Thyrocare Technologies Intrinsic Value
Thyrocare Technologies (THYROCARE) median intrinsic value is ₹169.28 from 10 valuation models (range ₹113–₹400), vs current price ₹564.25 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Thyrocare Technologies stock price NSE.
THYROCARE Valuation Methods Summary — DCF, Graham Number & P/E
Thyrocare Technologies intrinsic value across 10 models vs current price ₹564.25 — upside/downside and value range per method. Read THYROCARE ex-dividend dates for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹169.28 | ₹135.42 - ₹203.14 | -70.0% | EPS: ₹11.96, Sector P/E: 12x |
| Book Value Method | asset | ₹112.85 | ₹101.56 - ₹124.14 | -80.0% | Book Value/Share: ₹36.86, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹169.28 | ₹152.35 - ₹186.21 | -70.0% | Revenue/Share: ₹57.61, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹225.70 | ₹203.13 - ₹248.27 | -60.0% | EBITDA: ₹320.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹225.70 | ₹180.56 - ₹270.84 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹169.28 | ₹152.35 - ₹186.21 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹169.28 | ₹152.35 - ₹186.21 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹282.12 | ₹253.91 - ₹310.33 | -50.0% | ROE: 33.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹169.28 | ₹152.35 - ₹186.21 | -70.0% | EPS: ₹11.96, BVPS: ₹36.86 |
| Dividend Yield Method | dividend | ₹400.00 | ₹360.00 - ₹440.00 | -29.1% | DPS: ₹14.00, Target Yield: 3.5% |
THYROCARE Intrinsic Value vs Market Price — All Valuation Models
Thyrocare Technologies fair value range ₹113–₹400 vs current market price ₹564.25 across 10 valuation models. Analyse THYROCARE shareholder distribution to track promoter, FII and institutional holdings.
THYROCARE Intrinsic Value Analysis — Undervalued or Overvalued?
Thyrocare Technologies median intrinsic value ₹169.28, current price ₹564.25 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of THYROCARE?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Thyrocare Technologies (THYROCARE) is ₹169.28 (median value). With the current market price of ₹564.25, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹112.85 to ₹400.00, indicating ₹112.85 - ₹400.00.
Is THYROCARE undervalued or overvalued?
Based on our multi-method analysis, Thyrocare Technologies (THYROCARE) appears to be trading above calculated value by approximately 70.0%.
THYROCARE Financial Health — Key Ratios vs Industry Benchmarks
Thyrocare Technologies financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.29 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 33.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.23x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
THYROCARE Cash Flow Quality — Operating & Free Cash Flow
Thyrocare Technologies operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹213 Cr | ₹202 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹191 Cr | ₹165 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹168 Cr | ₹123 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹129 Cr | ₹110 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹113 Cr | ₹101 Cr | Positive Free Cash Flow | 8/10 |